Financial Performance - The company reported a significant increase in revenue, with total revenue reaching 1.5 billion yuan, representing a year-on-year growth of 15%[14]. - The company’s net profit for the year was reported at 300 million yuan, reflecting a 10% increase compared to the previous year[14]. - The company's operating revenue for 2021 was ¥4,737,565,985.43, representing a 7.97% increase compared to ¥4,388,047,897.50 in 2020[19]. - The net profit attributable to shareholders decreased by 20.49% to ¥306,922,328.31 in 2021 from ¥386,024,873.13 in 2020[19]. - The company’s revenue for 2021 was CNY 1,331.526 million, with a net profit of CNY 99.8364 million, accounting for 28.11% and 29.80% of the consolidated financial statements respectively[45]. - The company achieved a total operating revenue of CNY 4,737.57 million in 2021, representing a year-on-year growth of 7.97%[60]. - The company’s revenue from agricultural pesticides reached CNY 4,239.64 million, accounting for 89.49% of total revenue, with a growth of 9.04% year-on-year[60]. - The company’s revenue from veterinary drugs was CNY 477.25 million, representing a year-on-year increase of 9.11%[60]. Dividend Policy - The company plans to distribute a cash dividend of 3.00 yuan per 10 shares (including tax) to all shareholders[4]. - The total cash dividend, including other methods, reached ¥157,445,461.38, representing 100% of the profit distribution total[166]. - The company has implemented a cash dividend policy, distributing at least 20% of the annual distributable profit in cash, or 60% of the average annual distributable profit over three years[162]. - The company aims for a minimum cash dividend ratio of 80% for mature stages without major capital expenditures, and 40% with major expenditures[162]. - The company engages in regular communication with shareholders, especially minority shareholders, regarding dividend distribution proposals[164]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, particularly in Cambodia and Myanmar, to enhance its competitive edge[11]. - The company aims to achieve a revenue target of 1.8 billion yuan for the next fiscal year, indicating a growth forecast of 20%[14]. - The company is exploring strategic acquisitions to enhance its product portfolio and market reach, with a focus on companies in the agricultural sector[11]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[137]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[132]. Research and Development - The company has invested 200 million yuan in research and development for new pesticide formulations, aiming to launch three new products in the next fiscal year[14]. - The total R&D expenses for the year were ¥183,613,230.94, an increase of 4.85% compared to the previous year[74]. - The total R&D investment for 2021 was approximately ¥189.67 million, an increase of 2.21% compared to ¥185.57 million in 2020[78]. - The company has established five R&D platforms, including a GLP-certified laboratory, enhancing its capabilities in new drug discovery and pesticide technology development[50]. - The company has ongoing R&D projects for new pesticides, aiming for new product commercialization to create additional profit growth points[75]. Production and Capacity - The company has established a new production facility in Jiangsu province, expected to increase production capacity by 25%[14]. - The production capacity for the main product, raw pesticide, is designed at 83,300 tons/year, with a utilization rate of 84.16%[44]. - The company has a total designed capacity for pesticide formulations of 114,360 tons/year, with a utilization rate of 78.85%[44]. - The company is implementing a technical transformation project to produce 12,000 tons of aluminum phosphonate annually, with 80% of the output exported to European wine grape regions[52]. - The annual production project for 5,000 tons of Glyphosate by subsidiary Weiyuan Biochemical is expected to lower costs and emissions, improving market competitiveness[52]. Environmental Commitment - The company is committed to sustainability and has implemented new environmental practices in its production processes[11]. - The company has established comprehensive management systems for wastewater discharge and emergency response to environmental incidents[185]. - Limin Chemical reported a total pollutant discharge of 57.59 tons for COD, 6.33 tons for ammonia nitrogen, and 0.22 tons for cyanide, all within the regulatory limits[183]. - The company has continuously improved its pollution prevention technologies and increased investment in environmental protection initiatives[186]. - The company has signed a contract with China University of Mining and Technology for clean production technology services, focusing on improving production processes[186]. Risk Management - The company has identified potential risks including market competition and raw material price fluctuations, which may impact future performance[4]. - The company has implemented measures to mitigate risks associated with exchange rate fluctuations, customer defaults, and internal control risks related to derivative investments[93]. - The company is committed to enhancing environmental protection measures and carbon reduction capabilities in response to increasing ESG requirements[109]. - The company faces safety production risks due to the flammable, explosive, toxic, and corrosive nature of some raw materials, with production disruptions increasing safety risks[110]. - The company has a structured approach to performance incentives, linking rewards to both individual contributions and company performance[140]. Corporate Governance - The company has a robust governance structure with a board of directors, supervisory board, and specialized committees, ensuring compliance with corporate governance regulations[114]. - The independent directors actively participated in corporate governance and decision-making, providing valuable professional opinions on system improvement and operational development[147]. - The company has established a dedicated internal audit department to oversee internal controls and financial reporting[178]. - The company has a complete procurement, production, sales, and R&D system, allowing for independent market operations[119]. - The company maintains a clear separation of assets and operations from its controlling shareholders, ensuring independence in business operations[116]. Employee Management - The total number of employees at the end of the reporting period is 4,579, with 2,825 in production, 467 in sales, 872 in technology, and 354 in administration[155]. - The company encourages skill enhancement among employees, providing subsidies for skill certification and establishing a skill wage promotion channel[157]. - The company has a structured training program for middle and senior management to enhance leadership capabilities, including projects like "Learning from Huawei" and "Coaching Leadership"[159]. - The company has implemented a cash dividend policy, distributing at least 20% of the annual distributable profit in cash, or 60% of the average annual distributable profit over three years[162]. - The company has established an incentive mechanism for senior management, linking their income to performance, which has improved operational management[173].

Revenue and Profit - The company's revenue for the third quarter reached ¥1,160,817,380, representing a 24.00% increase year-over-year[2] - Net profit attributable to shareholders decreased by 87.00% to ¥8,690,507.28, while the net profit excluding non-recurring gains and losses dropped by 90.30% to ¥5,537,128.79[2] - The basic earnings per share fell by 67.94% to ¥0.06, and the diluted earnings per share also decreased by 67.94% to ¥0.06[2] - Net profit for the quarter was ¥292,207,347.02, a decrease from ¥417,304,439.12 in the same period last year[15] - The net profit attributable to the parent company for Q3 2021 was ¥269,950,448.87, a decrease of 27.8% compared to ¥373,916,723.77 in the same period last year[16] - The total comprehensive income attributable to the parent company was ¥269,815,324.59, down from ¥373,462,352.65 year-over-year[16] - The basic and diluted earnings per share for Q3 2021 were both ¥0.72, compared to ¥1.02 in the previous year, reflecting a decline of 29.4%[16] Assets and Liabilities - Total assets increased by 25.41% to ¥6,508,206,688.70 compared to the end of the previous year[2] - Total assets as of September 30, 2021, were ¥6,508,206,688.70, compared to ¥5,189,717,085.51 at the end of 2020[12] - Current assets increased to ¥2,905,093,453.16 from ¥2,179,584,951.25 year-over-year[10] - The total liabilities increased to ¥3,621,196,705.77 from ¥2,673,643,228.49 year-over-year[12] - The company’s retained earnings increased to ¥1,155,426,765.89 from ¥978,602,109.54[12] Cash Flow - Cash flow from operating activities showed a significant decline of 204.40%, indicating reduced cash inflow from sales[5] - Cash inflows from operating activities totaled ¥2,528,757,883.50, a decrease of 6.1% from ¥2,693,636,645.41 in the prior year[18] - The net cash flow from operating activities was negative at -¥245,085,620.65, contrasting with a positive cash flow of ¥234,762,255.02 in the same period last year[18] - Cash inflows from investment activities amounted to ¥302,899,015.18, significantly higher than ¥117,754,961.01 in the previous year[19] - The net cash flow from investment activities was -¥639,148,024.22, worsening from -¥235,015,649.54 year-over-year[19] - Cash inflows from financing activities reached ¥1,898,330,000.00, up from ¥1,028,294,716.02 in the same period last year[19] - The net cash flow from financing activities was positive at ¥995,865,505.58, compared to ¥77,583,201.82 in the previous year[19] - The ending balance of cash and cash equivalents was ¥767,349,882.32, an increase from ¥447,934,009.04 at the end of the same period last year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,793, with no preferred shareholders[7] - The top shareholder, Li Ming, holds 19.79% of the shares, while Li Xinsong holds 12.01%[7] Accounts Receivable - The company recorded a 153.64% increase in accounts receivable, attributed to uncollected receivables not yet settled[5] - The company reported a significant increase in accounts receivable, rising to ¥500,075,646.40 from ¥197,161,529.84[10] Operating Costs - Total operating costs amounted to ¥3,370,136,249.68, up from ¥3,186,458,997.52 year-over-year[15] Investments - Long-term investments rose to ¥297,070,363.23, compared to ¥278,152,182.17 in the previous period[11] Non-Recurring Gains and Losses - The company has no other non-recurring gains or losses beyond those reported[4]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,540,464,320.04, a decrease of 4.34% compared to the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥247,259,941.59, down 18.91% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥239,722,888.27, a decline of 20.60% compared to the previous year[21]. - Basic earnings per share were ¥0.66, down 21.43% from ¥0.84 in the same period last year[21]. - The company's total revenue for the reporting period was ¥2,540,464,320.04, a decrease of 4.34% compared to ¥2,655,711,956.92 in the previous year[40]. - The company's net profit attributable to shareholders decreased by 18.91% to ¥247,259,941.59 from ¥304,910,538.66 in the previous year[40]. - The company's cash flow from operating activities showed a significant decline of 273.36%, resulting in a net outflow of ¥282,707,788.97 compared to a net inflow of ¥163,079,587.93 in the previous year[40]. - The net profit after deducting non-recurring gains and losses for the first half of 2021 was approximately ¥260.90 million, a decrease of 23.78% compared to the same period in 2020[169]. - The net profit for the first half of 2021 was CNY 268,434,861.18, a decline of 22.36% from CNY 345,275,628.06 in the same period last year[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,349,701,550.84, an increase of 22.35% from the end of the previous year[21]. - The company's total assets reached ¥6.35 billion as of June 30, 2021, compared to ¥5.19 billion at the end of 2020[177]. - The company's total liabilities increased to ¥3.46 billion from ¥2.67 billion, showing a substantial rise in debt levels[177]. - The company's equity attributable to shareholders increased to approximately ¥2.73 billion from ¥2.37 billion, indicating growth in shareholder value[177]. - The company's asset-liability ratio increased to 54.42% as of June 30, 2021, up from 51.52% at the end of 2020, representing a change of 2.90%[169]. Cash Flow - The net cash flow from operating activities was -¥282,707,788.97, a significant decrease of 273.36% compared to the same period last year[21]. - The company's cash and cash equivalents at the end of the reporting period were ¥1,147,710,111.60, representing 18.08% of total assets[49]. - The total cash and cash equivalents at the end of the first half of 2021 were 930,406,585.14, up from 599,911,652.96 at the end of the first half of 2020, reflecting a growth of approximately 55.1%[193]. - The cash flow from financing activities showed a net increase of 661,649,787.72 CNY, with total cash inflow of 995,750,000.00 CNY[196]. - The total cash outflow for financing activities was 334,100,212.28 CNY, primarily due to debt repayment and dividend distribution[196]. Research and Development - The company's R&D investment increased by 9.55% to ¥89,309,896.54 from ¥81,520,939.66 year-on-year[40]. - The company has established multiple research and development centers to enhance innovation capabilities and improve product traceability[107]. - Research and development expenses were CNY 79,294,565.67, slightly up from CNY 79,026,896.45 in the previous year[182]. Market and Industry Position - The pesticide industry in China has seen rapid development, with over 1,000 registered products and more than 400 production enterprises[29]. - The company is a key player in the pesticide sector, holding the largest production capacity for several key products, including mancozeb and fludioxonil[30]. - The veterinary medicine sector is also growing, with the company’s subsidiary, Weiyuan Pharmaceutical, certified by multiple international standards[30]. - The company's main products include fungicides, insecticides, herbicides, and veterinary medicines, with a focus on both raw materials and formulations[31]. - The revenue from the pesticide segment was ¥2,277,050,697.39, accounting for 89.63% of total revenue, with a year-on-year decrease of 4.35%[42]. Environmental Management - The company has established comprehensive environmental management regulations, including wastewater and air pollution control measures[80]. - The company has implemented a pollution liability insurance policy to comply with environmental regulations[80]. - Limin Holdings has a total of 14 emission outlets for volatile organic compounds, with emissions not exceeding regulatory standards[77]. - The company has established three comprehensive wastewater treatment facilities with a daily processing capacity of 7,800 tons, ensuring treated wastewater meets discharge standards before entering the local sewage treatment plant[81]. - The company has not faced any environmental administrative penalties or major pollution incidents during the reporting period, demonstrating compliance with environmental regulations[84]. Risk Management - The company faces various risks including market competition, raw material price fluctuations, and integration risks from acquisitions[5]. - Raw material costs constitute a large portion of operating costs, and fluctuations in prices can significantly affect gross margins and profitability; the company plans to enhance procurement controls and extend upstream in the supply chain to mitigate these risks[64]. - The company has implemented risk control measures for foreign exchange transactions, including internal control systems to mitigate potential risks[59]. Shareholder and Corporate Governance - The company has no significant litigation or arbitration matters during the reporting period[116]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[112]. - The company has no preferred shares or corporate bonds outstanding as of the reporting period[157][161]. - The total number of common shareholders at the end of the reporting period is 23,010[151]. - The largest shareholder, Li Ming, holds 73,734,050 shares, representing 19.79% of total shares[152]. Future Outlook - The company’s future outlook includes continued investment in technology upgrades and market expansion strategies[30]. - The company plans to expand its market presence, focusing on new product development and technological advancements[199]. - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[199].

Revenue and Profit - Revenue for Q1 2021 was CNY 1,278,419,638.94, a decrease of 3.53% compared to CNY 1,325,240,428.99 in the same period last year[7] - Net profit attributable to shareholders increased by 12.96% to CNY 160,851,094.64 from CNY 142,400,624.33 year-on-year[7] - Basic earnings per share decreased by 14.00% to CNY 0.43 from CNY 0.50 in the same period last year[7] - The company reported a net profit attributable to shareholders increased by 12.96%, driven by a higher ownership percentage in the Weiyuan asset group[14] - Net profit for the first quarter was CNY 173,633,180.46, up from CNY 167,104,532.33 year-over-year[42] - The company reported a total comprehensive income of CNY 173,802,109.00, compared to CNY 167,480,278.72 in the previous period[43] Cash Flow - Net cash flow from operating activities was negative at CNY -368,442,247.53, a decline of 674.65% compared to CNY -47,562,155.78 in the previous year[7] - The cash flow from operating activities decreased by 674.65% due to increased cash payments for goods and services[14] - Cash inflow from operating activities totaled CNY 646,867,752.97, a decrease from CNY 786,390,300.43 in the previous period[49] - Cash outflow from operating activities was CNY 1,015,310,000.50, compared to CNY 833,952,456.21 in the prior period, leading to a net cash flow from operating activities of -CNY 368,442,247.53[50] - The company experienced a cash flow outflow from investment activities of -CNY 237,802,493.07, compared to -CNY 27,713,085.41 in the previous period[50] - The company received CNY 17,070,139.68 in tax refunds during the quarter, compared to CNY 10,686,417.12 in the previous period[49] Assets and Liabilities - Total assets increased by 16.79% to CNY 6,061,291,065.44 from CNY 5,189,717,085.51 at the end of the previous year[7] - Current assets rose to CNY 2,901,589,663.45, up from CNY 2,179,584,951.25, indicating an increase of about 33.1%[32] - Total liabilities rose to CNY 3,147,556,827.38 from CNY 2,673,643,228.49, representing an increase of about 17.7%[34] - Total equity increased to CNY 2,913,734,238.06 from CNY 2,516,073,857.02, showing a growth of approximately 15.8%[35] - The total owner's equity attributable to the parent company increased to CNY 2,753,887,027.71 from CNY 2,368,330,894.91, reflecting a growth of around 16.2%[35] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,777[10] - The largest shareholder, Li Ming, holds 19.79% of the shares, amounting to 73,734,050 shares[10] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11] Investments and Projects - The company successfully issued 980 million yuan in convertible bonds, with funds allocated to investment projects[15] - The company is in trial production for several projects, including a 500-ton benzoyl methyl ring project and a 10,000-ton series product project[15] - The construction of new green bio-product manufacturing projects has commenced[15] Financial Management - The company has established a dedicated account storage system for managing raised funds to protect the rights of minority investors[22] - The company has signed tripartite supervision agreements with multiple banks to ensure proper management of raised funds[22] - There were no violations regarding external guarantees during the reporting period[26] - The company reported no non-operating occupation of funds by controlling shareholders or related parties during the reporting period[27] Other Financial Metrics - The company’s investment income fell by 70.39% due to market fluctuations affecting a joint venture[14] - The company allocated RMB 290 million of the raised funds to supplement working capital on March 5, 2021[23] - The company approved the use of RMB 142.75 million of raised funds to replace pre-invested self-raised funds on March 26, 2021[23] - The company confirmed an investment income of RMB 2.19 million from derivative investments during the reporting period[26] - The fair value loss from derivative investments was RMB 0.7335 million, calculated based on market prices as of the balance sheet date[26]

Financial Performance - The company achieved a revenue of 438,804.79 million CNY, representing a year-on-year growth of 54.91%[46]. - The net profit attributable to shareholders reached 38,602.49 million CNY, with a year-on-year increase of 19.92%[46]. - The company's operating revenue for 2020 was CNY 4,388,047,897.50, representing a 54.91% increase compared to CNY 2,832,674,577.01 in 2019[19]. - The net profit attributable to shareholders for 2020 was CNY 386,024,873.13, a 19.92% increase from CNY 321,894,664.90 in 2019[19]. - The net profit after deducting non-recurring gains and losses was CNY 364,661,837.18, up 24.73% from CNY 292,368,139.31 in 2019[19]. - The net cash flow from operating activities reached CNY 903,335,207.94, a significant increase of 358.63% compared to CNY 196,965,174.87 in 2019[19]. - The total assets at the end of 2020 were CNY 5,189,717,085.51, an 8.86% increase from CNY 4,767,286,264.84 at the end of 2019[19]. - The basic earnings per share for 2020 were CNY 1.05, reflecting a 17.98% increase from CNY 0.89 in 2019[19]. - The company received government subsidies totaling CNY 22,627,936.62 in 2020, accounting for 5.86% of the net profit for the year[25]. Dividend Policy - The company distributed a cash dividend of 2.50 CNY per 10 shares, totaling 93,128,610.25 CNY for the year 2020, which represents 24.13% of the net profit attributable to ordinary shareholders[119]. - The cash dividend policy stipulates that at least 20% of the distributable profit must be distributed in cash annually, with a minimum of 40% if there are significant capital expenditure plans[114]. - The company’s cash dividend distribution is aligned with its articles of association and has been approved by the shareholders' meeting[117]. - The company has a policy to communicate with minority shareholders regarding dividend proposals, ensuring their opinions are considered[116]. - The cash dividend distribution for 2020 was 100% of the total profit distribution amount[121]. Market Position and Strategy - The company is positioned to benefit from the shift towards high-efficiency, low-toxicity pesticides, which are expected to dominate the market due to increasing environmental awareness[28]. - The company is a leading domestic pesticide producer with significant capacities in various products, including the largest production of mancozeb and other key pesticides[31]. - The company has a market presence in over 80 countries and regions, indicating strong international competitiveness[31]. - The company’s sales strategy includes both domestic and international markets, with a focus on direct sales to large farms and distributors for smaller packages[37]. - The company aims to strengthen its market position through industry consolidation and technological advancements[30]. Research and Development - The company is actively involved in the research and development of environmentally friendly products in response to stricter environmental regulations[30]. - The company has established a complete system for R&D, procurement, production, and sales, enhancing operational efficiency[37]. - The number of R&D personnel rose by 58.01% to 730, with R&D investment amounting to ¥185.57 million, which is 4.23% of operating revenue[74]. - The company has a total of 8 authorized patents related to its main products, enhancing its research and development capabilities[51]. Risk Management - The company faces various risks, including market competition and raw material price fluctuations, which could impact future performance[5]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements[5]. - The company has a risk management framework in place to address various risks including market, liquidity, credit, and operational risks[92]. - The company has established performance commitment agreements to mitigate risks associated with the Weiyuan asset group's operational performance[108]. Environmental Management - The company has received multiple environmental management certifications, including ISO 9001, ISO 14001, and OHSAS 18001, demonstrating its commitment to environmental protection and sustainable development[174]. - The company has implemented a "three simultaneous" policy for environmental protection during project construction, ensuring all projects pass environmental approvals and inspections[174]. - The company has not faced any environmental administrative penalties or major pollution incidents during the reporting period[179]. - The company has established and improved environmental management regulations and emergency plans, including various management systems and emergency response plans[175]. Safety Management - The company has a safety management team consisting of 29 dedicated safety personnel and has maintained its safety production license since 2006[158]. - The total safety investment for 2020 amounted to approximately 7.7 million RMB, with a focus on enhancing safety management systems[159]. - The company organized 126 emergency drills throughout the year, improving employees' emergency response capabilities[161]. - The company has implemented a dual control mechanism for risk management, identifying and addressing potential risks across various departments[160]. Subsidiary Performance - The net profit of the subsidiary Limin Chemical reached RMB 134,358,502, contributing significantly to the overall financial performance of the company[102]. - The company’s subsidiary Weiyuan Biochemical reported a net profit of RMB 109,288,335, indicating strong performance in the pesticide production sector[102]. - The total assets of the subsidiary Weiyuan Biochemical stand at RMB 1,629,928,510, reflecting its substantial market presence[102]. Financial Oversight - The financial advisor for the reporting period was Zhongyuan Securities Co., Ltd., indicating ongoing financial oversight[18]. - The company appointed Tianheng Certified Public Accountants (Special General Partnership) as its auditor for the fiscal year 2020, with an audit fee of 1.1 million yuan[134].

第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人李新生、主管会计工作负责人王娟及会计机构负责人(会计主管 人员)侯立立声明：保证季度报告中财务报表的真实、准确、完整。 利民控股集团股份有限公司 2020 年第三季度报告全文 利民控股集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 利民控股集团股份有限公司 2020 年第三季度报告全文 2 利民控股集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,038,579,430.13 | | 4,767,286,264.84 | 5.69% | | 归属于上市公司股东的净资产 | 2,333,751,137 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 2,655,711,956.92, representing a 144.20% increase compared to CNY 1,087,518,713.27 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached CNY 304,910,538.66, a 53.47% increase from CNY 198,682,889.47 in the previous year[19]. - The net cash flow from operating activities was CNY 163,079,587.93, showing a significant increase of 4,208.12% compared to CNY 3,785,400.88 in the same period last year[19]. - Basic earnings per share increased to CNY 0.84, up 52.73% from CNY 0.55 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 301,933,670.21, a 60.17% increase from CNY 188,506,142.80 in the previous year[19]. - The company achieved a total revenue of CNY 2.66 billion, representing a year-on-year growth of 144.2%[38]. - Net profit attributable to shareholders reached CNY 305 million, an increase of 53.47% compared to the previous year[38]. - The company reported a significant increase in other income to CNY 14,265,838.81 in the first half of 2020, compared to CNY 4,820,163.97 in the same period of 2019, reflecting improved operational efficiency[174]. - The net profit for the first half of 2020 reached CNY 345.28 million, compared to CNY 213.40 million in the first half of 2019, indicating an increase of about 62%[177]. - The total comprehensive income for the first half of 2020 was CNY 344.72 million, compared to CNY 213.45 million in the first half of 2019, representing an increase of approximately 61%[177]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,223,283,767.09, a 9.57% increase from CNY 4,767,286,264.84 at the end of the previous year[19]. - The total liabilities increased to CNY 2,661,157,935.38 as of June 30, 2020, compared to CNY 2,471,948,348.16 at the end of 2019, marking an increase of about 7.7%[169]. - The total equity attributable to the parent company increased to CNY 2,297,434,722.43 as of June 30, 2020, compared to CNY 2,070,939,909.53 at the end of 2019, representing a growth of about 10.9%[169]. - The company's total assets as of June 30, 2020, were CNY 5,223,283,767.09, up from CNY 4,767,286,264.84 at the end of 2019, reflecting a growth of approximately 9.5%[169]. - The total amount of special reserves at the end of the current period was 3,607.10 million yuan[195]. - The total liabilities at the end of the first half of 2020 were 2,562 million yuan, showing a manageable debt level[192]. Cash Flow - The company's cash flow from operating activities increased by 4,208.12% to CNY 163.08 million, attributed to higher sales collections[38]. - The cash flow from operating activities for the first half of 2020 was CNY 1.85 billion, significantly higher than CNY 765.38 million in the same period of 2019, indicating a growth of about 142%[183]. - The total cash inflow from investment activities was ¥113,836,751.63, while cash outflow was ¥134,547,799.70, resulting in a net cash flow of -¥20,711,048.07 for the first half of 2020[185]. - The net cash flow from financing activities was ¥78,292,066.06, a decrease from ¥246,652,478.14 in the first half of 2019, highlighting a shift in financing strategy[185]. Research and Development - Research and development investment increased by 169.17% to CNY 81.52 million, driven by the inclusion of the Weiyuan asset group[38]. - Research and development expenses for the first half of 2020 were CNY 79,026,896.45, up from CNY 29,466,082.77 in the same period of 2019, indicating a focus on innovation and product development[174]. - The company holds 140 authorized patents, including 51 invention patents, and has participated in the formulation of 43 international and national standards[31]. Market Position and Strategy - The company is a key player in the domestic pesticide industry, holding the largest production capacity for several key products, including mancozeb and cyprodinil, and is recognized for its significant role in the biopesticide sector[28]. - The company has established a strong market presence with a distribution network covering 30 provinces and municipalities, supported by over 1,000 distributors and nearly 30,000 retailers[32]. - The company is positioned to benefit from industry consolidation trends, with a focus on technological leadership and flexible operations to enhance international competitiveness[28]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[200]. Environmental Management - The company has achieved ISO 14001 environmental management certification and is recognized for its clean production technologies, contributing to its competitive advantage in environmental safety[33]. - The company has implemented a comprehensive environmental management system, including regulations for wastewater discharge and air pollution prevention, ensuring compliance with environmental laws[108]. - The company has established a dedicated environmental management organization and appointed environmental supervisors in each workshop to enhance oversight and compliance[108]. - The company has signed an environmental pollution liability insurance contract, ensuring financial protection against potential environmental damages[108]. - The company has not faced any environmental administrative penalties or major pollution incidents during the reporting period, demonstrating compliance with environmental regulations[111]. Shareholder and Equity Information - The total number of shareholders at the end of the reporting period was 21,657, with significant shareholders including Li Ming holding 19.79% and Li Xinsheng holding 12.01%[147]. - The company reported a decrease in basic and diluted earnings per share and net assets per share due to the share conversion[143]. - The company’s stock repurchase program is ongoing, with no specific updates provided in the report[142]. - The company’s capital structure remains stable, with a significant portion of shares held by insiders and institutional investors[147]. Social Responsibility - The company donated a total of 100,000 RMB for poverty alleviation efforts in Xinyi City and provided additional material support worth 5,500 RMB[132]. - The total investment in poverty alleviation efforts amounted to 273,000 RMB, including 100,000 RMB for industry development projects and 65,000 RMB for educational support[133]. - The company has committed to ongoing poverty alleviation efforts targeting economically disadvantaged villages in Xinyi City[135].

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,325,240,428.99, representing a 234.17% increase compared to ¥396,577,307.05 in the same period last year[7] - Net profit attributable to shareholders was ¥142,400,624.33, up 72.50% from ¥82,549,278.89 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥143,971,410.74, an increase of 80.26% compared to ¥79,867,853.66 in the previous year[7] - The basic earnings per share rose to ¥0.5, a 72.41% increase from ¥0.29 in the same period last year[7] - The total operating profit for the first quarter was approximately CNY 204.95 million, compared to CNY 91.60 million in the same period last year, representing a year-over-year increase of 123.8%[35] - The total profit for the first quarter was CNY 199.92 million, compared to CNY 91.52 million last year, an increase of 118.4%[35] - The total comprehensive income for the period was CNY 167.48 million, compared to CNY 84.02 million in the prior year, indicating a growth of 99.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,977,113,678.80, reflecting a 4.40% increase from ¥4,767,286,264.84 at the end of the previous year[7] - Total liabilities as of March 31, 2020, were CNY 2,511,335,177.62, compared to CNY 2,471,948,348.16 at the end of 2019[28] - Total assets decreased to CNY 4,977,113,678.80 from CNY 4,767,286,264.84[28] - Long-term equity investments increased to CNY 1,925,979,413.39 from CNY 1,208,440,858.18[30] Cash Flow - The net cash flow from operating activities improved to -¥47,562,155.78, a 51.78% improvement from -¥98,643,992.52 in the same period last year[7] - The company reported a cash inflow from operating activities of CNY 786.39 million, compared to CNY 238.85 million in the same period last year, representing a growth of 228.5%[41] - The net cash flow from operating activities was -47,562,155.78 yuan, compared to -98,643,992.52 yuan in the previous period, indicating an improvement[43] - The total cash inflow from investment activities was 52,912,747.69 yuan, while cash outflow was 80,625,833.10 yuan, resulting in a net cash flow of -27,713,085.41 yuan[43] - The net cash flow from financing activities was 45,980,609.37 yuan, compared to -2,071,505.79 yuan in the previous period, showing a significant increase[44] - The company reported a net decrease in cash and cash equivalents of -27,861,945.01 yuan for the period[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,298[10] - The top shareholder, Li Ming, holds 19.79% of the shares, totaling 56,718,500 shares[10] Expenses - Operating costs amounted to CNY 1,137,430,170.47, up from CNY 346,104,462.74 in the previous period[34] - Research and development expenses surged by 271.97% mainly from the consolidation of the Weiyuan asset group[14] - Research and development expenses increased to CNY 39,392,281.91 from CNY 10,590,308.47 year-on-year[34] - The company reported a significant increase in tax expenses, with a rise of 627.96% due to increased corporate income tax payable[14] Other Income and Investments - The company received government subsidies amounting to ¥2,739,921.14 during the reporting period[8] - The company reported a significant increase in other income to CNY 2,739,921.14 from CNY 3,308,648.58[34] - The investment income for the period was CNY 29.40 million, down from CNY 41.04 million in the previous year, indicating a decrease of 28.3%[38] Organizational Changes - The company established a wholly-owned subsidiary to optimize organizational structure and improve management efficiency, with asset transfer valued at approximately 698 million yuan[15]

Financial Performance - The company's operating revenue for 2019 was ¥2,832,674,577.01, representing an increase of 86.46% compared to ¥1,519,182,041.58 in 2018[19]. - The net profit attributable to shareholders for 2019 was ¥321,894,664.90, a growth of 56.17% from ¥206,113,576.77 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥292,368,139.31, up 47.52% from ¥198,193,103.79 in 2018[19]. - The basic and diluted earnings per share for 2019 were both ¥1.18, reflecting a 59.46% increase from ¥0.74 in 2018[19]. - The total assets at the end of 2019 reached ¥4,767,286,264.84, marking a 74.29% increase from ¥2,735,314,477.10 at the end of 2018[19]. - The company reported a net cash flow from operating activities of ¥196,965,174.87, which is a decrease of 14.94% compared to ¥231,571,605.77 in 2018[19]. - The company achieved a revenue of 2.833 billion yuan, representing a year-on-year growth of 86.46%[38]. - The net profit attributable to shareholders reached 322 million yuan, an increase of 56.17% compared to the previous year[38]. Business Operations - The company has not changed its main business since its listing, indicating stability in its operations[17]. - The company is a key player in the domestic pesticide production industry, with significant production capacity in various pesticide categories[30]. - The company has established itself as a leader in the biopesticide sector, with sales ranking among the top in both domestic and international markets[30]. - The company is actively involved in the research and development of new products, focusing on high-efficiency, low-toxicity, and environmentally friendly pesticides[30]. - The company has a strong market presence, covering over 80 countries and regions, and is recognized as a participant in international standards and a developer of national standards[30]. - The company completed a significant asset acquisition, gaining control of Weiyuan Biochemical, Weiyuan Pharmaceutical, and New Weiyuan, which were included in the consolidated financial statements from May 31, 2019[41]. - The company established a wholly-owned subsidiary, Limin Chemical, to optimize its organizational structure and improve management efficiency[41]. Risk Management - The company emphasizes the importance of risk awareness regarding market competition, raw material price fluctuations, and other operational risks[5]. - The company faces market competition risks, with potential price declines and reduced gross margins due to increased investments from competitors; it aims to optimize technology and develop new products to maintain competitive advantages[94]. - Raw material costs significantly impact the company's operating costs; fluctuations in raw material prices could lower gross margins, prompting the company to strengthen procurement controls and extend upstream in the supply chain[95]. - Environmental regulations are becoming stricter, increasing the company's investment in waste management and environmental protection, which may affect profitability; the company will continue to implement clean production and optimize waste treatment technologies[95]. - Post-acquisition integration risks exist, requiring optimization in corporate culture and business synergy to maximize acquisition benefits; the company will establish control mechanisms to manage and oversee the acquired entities[95]. Investment and Capital Management - The company completed a capital increase of 480 million yuan, with a 60% stake acquired through a loan for the acquisition of agricultural and veterinary drugs[73]. - The company has committed a total investment of RMB 74,019.66 million, with a cumulative investment of RMB 76,339.35 million, achieving 102.11% of the planned investment[81]. - The expected benefits from the acquisition of Weiyuan Asset Group are projected at RMB 7,913.66 million, confirming the project's feasibility[84]. - The company has utilized self-raised funds of RMB 14,015.28 million to advance the high-efficiency pesticide project before the official fundraising was completed[82]. - The company plans to enhance market analysis and expand its market presence in 2020, aiming for synchronized growth in revenue and profit[92]. Shareholder Returns - The company reported a profit distribution plan to distribute a cash dividend of 3 RMB per 10 shares (including tax) based on a total of 286,557,570 shares[5]. - The company’s profit distribution policy emphasizes stable returns to investors, with a minimum of 20% of distributable profits to be distributed in cash, contingent on meeting certain financial conditions[100]. - The company aims to maintain a cash dividend ratio of at least 80% for mature stages without major capital expenditures, ensuring sustainable growth and investor returns[101]. - The total distributable profit for 2019 was 686,232,815.39 RMB, with the cash dividend representing 100% of the profit distribution[109]. - The cash dividend for 2018 was 3.50 RMB per 10 shares, amounting to 99,225,199.50 RMB, which represented 48.14% of the net profit attributable to shareholders[106]. Environmental Management - The company has achieved ISO 14001 certification and been recognized as a model for social responsibility in the industry[35]. - The company has established three comprehensive wastewater treatment facilities with a daily processing capacity of 7,800 tons, ensuring compliance with discharge standards[167]. - The company has received multiple environmental certifications, including ISO9001, ISO14001, and OHSAS18001, demonstrating its commitment to quality and environmental management[165]. - The company has implemented a comprehensive solid waste management system, ensuring proper handling and disposal of hazardous waste through qualified third-party services[168]. - The company has conducted 22 environmental emergency drills in its production workshops in 2019, enhancing its preparedness for potential environmental incidents[168]. Corporate Governance - The independent directors have fulfilled their responsibilities and ensured that minority shareholders' rights are adequately protected[104]. - The company has established a complete decision-making process for its cash dividend policy, ensuring compliance with regulations[104]. - The company has communicated with minority shareholders to gather their opinions before finalizing the cash dividend proposal[104]. - The company has confirmed that all commitments made by its executives and major shareholders have been fulfilled on time[114]. - The company has established a framework for monitoring and reporting on the fulfillment of these commitments[112].

Financial Performance - Operating revenue for the period reached CNY 925,729,370.45, representing a 152.99% increase year-on-year[7] - Net profit attributable to shareholders increased by 85.77% to CNY 87,794,989.38 for the period[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 71,425,763.64, up 61.07% year-on-year[7] - Basic earnings per share rose by 93.75% to CNY 0.31[7] - The company expects a net profit increase of 50% to 70% for the fiscal year 2019, with projected net profit ranging from 30,917.04 to 35,039.31 million yuan[23] - The total operating revenue for the third quarter was CNY 925.73 million, a significant increase from CNY 365.92 million in the same period last year, representing a growth of 153.5%[42] - The net profit for the quarter reached CNY 101.37 million, compared to CNY 47.41 million in the previous year, reflecting a growth of 113%[43] - Total operating revenue for the period reached ¥2,013,248,083.72, a significant increase of 86.5% compared to ¥1,078,350,928.54 in the previous period[48] - Net profit attributable to the parent company was ¥286,477,878.85, representing an increase of 90.5% compared to ¥150,216,499.57 in the previous year[50] - The company achieved a net profit margin of approximately 15.6% for the period, compared to 14% in the previous year[50] Assets and Liabilities - Total assets increased by 70.52% to CNY 4,664,193,676.24 compared to the end of the previous year[7] - Current assets increased to CNY 1,931,019,848.10 as of September 30, 2019, up from CNY 1,441,890,596.27 at the end of 2018, representing a growth of approximately 34.1%[32] - Total non-current assets reached CNY 2,733,173,828.14, up from CNY 1,293,423,880.83, indicating an increase of approximately 111.7%[33] - Total liabilities increased to CNY 2,254,068,969.22 from CNY 858,483,527.29, representing a growth of about 162.5%[34] - The total liabilities increased to CNY 987.74 million from CNY 673.81 million, marking a rise of 46.6%[40] - Total liabilities amounted to CNY 858,483,527.29, with non-current liabilities totaling CNY 80,292,274.50[68] - The company reported a total asset value of 2,735,314,477.10 CNY as of the end of the reporting period[66] Cash Flow - Cash flow from operating activities decreased by 25.05% to CNY 91,838,986.11 compared to the previous period[7] - Cash flow from financing activities increased by 1236.63% due to a substantial rise in bank loans received[17] - The company’s cash flow from operating activities was not detailed, but the increase in net profit suggests improved operational efficiency[43] - Cash flow from operating activities generated ¥1,645,237,799.20, compared to ¥943,767,835.30, indicating a growth of about 74%[58] - Cash inflow from financing activities totaled 722,272,390.00 CNY, significantly higher than 350,000,000.00 CNY in the previous year[63] Shareholder Information - The company reported a total of 11,070 common shareholders at the end of the reporting period[11] - The top shareholder, Li Ming, holds 19.97% of the shares, amounting to 56,718,500 shares[11] Research and Development - Research and development expenses increased by 86.21% as a result of the Weiyuan asset group's R&D costs being included in the consolidated financials[16] - Research and development expenses for the quarter were CNY 36.85 million, significantly higher than CNY 11.37 million in the previous year, indicating an increase of 224%[42] - R&D expenses increased to ¥31,670,501.68 from ¥27,730,402.91, representing a growth of approximately 14% year-over-year[54] Acquisitions and Investments - The company completed the acquisition of the Weiyuan asset group, significantly impacting financial metrics such as total assets and liabilities[16] - The company established a wholly-owned subsidiary, Limin Chemical Co., Ltd., to optimize organizational structure and improve operational efficiency[18] - The company received a performance compensation payment of 17,604,792.80 yuan from Hebei Shuangji, fulfilling obligations from previous performance commitments[20] - Investment income for the quarter was CNY 50.31 million, compared to CNY 27.83 million, showing an increase of 80.5%[42] - Investment income surged to ¥241,294,721.28 from ¥69,932,985.38, marking an increase of approximately 245%[54] Financial Adjustments and Standards - The company has not restated prior financial statements under the new financial instrument standards, impacting the retained earnings and other comprehensive income[69] - The company has implemented expected credit loss provisions for financial assets measured at amortized cost and fair value[69] - The company has adjusted its financial reporting to comply with new financial instrument standards, affecting the classification and measurement of financial assets[69] Other Financial Metrics - The company reported a significant increase in other receivables, which rose to CNY 69,802,358.52 from CNY 6,562,751.95, marking an increase of approximately 964.5%[32] - The company reported a basic and diluted earnings per share of CNY 0.31, up from CNY 0.16 in the same quarter last year[44] - The total comprehensive income for the period was ¥326,762,585.05, compared to ¥152,243,731.34 in the previous year, indicating an increase of about 114%[55]